Search Results

You are looking at 1 - 10 of 166 items for :

  • hyperlipidemia x
Clear All
Open access

Mai-Lan Liu, Shen Xie, Si-An Pan, Mi Liu and Xiao-Rong Chang

cardiovascular events in middle-aged group. Chinese Journal of Cardiology 2004,32(7):643-647. 4 Arrow WS. Management of hyperlipidemia with statins in the older patient. Clin Interv Aging,2006,1(4):433-438. 5 Fang LI, Yan NONG. Overview of acupuncture treatments on hyperlipermia. Journal of Jiangxi University of Traditional Chinese Medicine 2010, 22,(4):87-91. 6 Zhan-Qiang MA. Meta analysis on the safety and effectiveness of acupuncture on hyperlipemia. Henan Traditional Chinese Medicine 2012

Open access

Dana-Teodora Anton-Pǎduraru, Carmen Oltean, Laura Mihaela Trandafir and Cristina Rusu

. *** Tryple X syndrome. http://en.wikipedia.org/wiki/Triple_X_syndrome 5. *** Clinical practice guidelines on dyslipidaemia. www.acadmed.org.my/view_file.cfmfileid=186. 6. Clauss S. Pediatric hyperlipidemia. www.childrensnational.org. 7. Rohrs H, Berger S. Pediatric lipid disorders in clinical practice. http://emedicine.medscape.com/article/1825087-overview 8. Gidding SS. An emerging dyslipidemia: assessing future cardio-vascular risk in children. Contemp Pediatr 29: 14-24, 2012. 9. Kleinman R

Open access

Violeta Iric-Cupic, Srdjan Milanov, Goran Davidovic, Vladimir Zdravkovic, Jelena Vuckovic-Filipovic, Rada Vucic and Ivan Simic

and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am Cardiol. 2000; 86: 250-2. 10. Jones P., Davidson MH., Stein EA., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003; 92: 152-60. 11. Malloy JM., Kane PJ. Agents used in Hyperlipidemia. In Basic & Clinical Pharmacology. Katzung GB. Ed. 581-95. Lange Medical Books/Mc Graw-Hill-Medical publishing division, New York, 2001

Open access

Hilal Yücel, Abitter Yücel, Hamdi Arbağ, Erkan Cure, Mehmet Akif Eryilmaz and Ahmet Bedri Özer

REFERENCES 1. FOX KM., WANG L., GANDRA SR., QUEK RG., LI L., BASER O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study . BMC Cardiovasc Disord. 2016; 16 :13. 2. CANIS M., OLZOWY B., WELZ C., SUCKFULL M., STELTER K. Simvastatin and Ginkgo biloba in the treatment of subacute tinnitus: a retrospective study of 94 patients . Am J Otolaryngol. 2011; 32 (1):19-23. 3. MARON DJ., FAZIO S., LINTON MF. Current perspectives on Statins . Circulation. 2000; 18; 101 (2

Open access

Bulent Yildiz, Halil Kavgaci, Evren Fidan, Erdal Gungor, Halil O. Ersoz, Feyyaz Ozdemir and Fazil Aydin

Abstract

Background: Severe hyperlipidemia secondary to capecitabine, an oral fluoropyrimidine, is a very rare condition. There are no reported cases of hyperlipidemia associated with Uracil/tegafur (UFT). Objective: Report UFT-induced severe hyperlipidemia. Method: A 71-year-old male patient with metastatic colorectal cancer receiving capecitabine treatment was hospitalized at the end of the eighth cycle with the complaint of fatigue. Capecitabine treatment was discontinued in the patient in whom severe hyperlipidemia was detected together with disease progression. Gemphibrozile 1200 mg/day was initiated; patient’s triglyceride level and serum cholesterol decreased from 1768 to 149 mg/dL and from 497 to 99 mg/dL, respectively, five weeks later. The patient started to receive UFT chemotherapy and after the second cycle, he presented to our hospital again with the complaints of fatigue, headache, and yellow vision. The investigations revealed a serum triglyceride level of 4115 mg/dL and a cholesterol level of 734 mg/dL. Results: UFT chemotherapy was discontinued and lipopheresis was administered for three consecutive days, and gemphibrozile was initiated again at a dose of 1200 mg/day. The clinical presentation might be due to oral fluoropyrimidine. Three weeks later, serum cholesterol and triglyceride levels decreased to 106 and 403 mg/dL, respectively. Conclusion: This case is a unique case of hyperlipidemia secondary to UFT. Monitoring of lipid levels, when using Fluoropyrimidine, as well as hemograms, liver and renal functions would be appropriate.

Open access

Urvash Goyal, Ritika Arora and Geeta Aggarwal

. Parkinson, Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs, Lipids 7 (1972) 68-74. 12. International Conference on Harmonization Q1A(R2) Stability Testing Guidelines: Stability Testing of New Drug Substances and Products , ICH 2003. 13. S. X. Cui, S. F. Nie, L. Li, C. G. Wang and W. S. Pan, Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine, Drug Dev. Ind. Pharm. 35 (2009) 603-611; DOI: 10.1080/03639040802488089. 14. J. Cui, B. Yu

Open access

Hao-feng Xiong, Jing-yuan Liu, Hao-dong Cai and Jun Cheng

Abstract

Acute pancreatitis in pregnancy (APIP) is rare and the reasons for APIP are biliary disease and congenital or acquired hypertriglyceridemia, which could occur during any trimester but more than 50% cases happened during the third trimester. In this report, one case of a young pregnant woman, a HBV carrier in her 37th week + 5 d of gestation, was admitted to Emergency Department due to acute abdominal pain, vomiting and diarrhea. The patient was in antiretroviral treatment with telbivudine from 28 weeks of gestation to prevent motherto- child transmission of HBV. Laboratory tests demonstrated hypertriglyceridemia, abdominal computed tomography scan revealed peripancreatic edema. Hyperlipidemic pancreatitits was primary diagnosed and the patient was admitted to the intensive care unit. Considering the possible role in the pathogenesis of pancreatitis, telbivudine was interrupted after birth giving. After supportive treatment, her condition gradually improved. Since it is the first description of APIP during treatment with telbivudine, the association between pregnancy, hyperlipidemia, telbivudine and acute pancreatitis has been well investigated.

Open access

Nahla Al-Bayyari, Nesreen Saadeh, Raed Hailat and Safaa Al-Zeidaneen

CD, Newman AB. Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med 158: 1761-1768, 1998. 5. Heart Protection Study Collaborative Group MRC/BHF. Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 7-22, 2002. 6. Walsh JME, Pignone M. Drug treatment for hyperlipidemia in women. JAMA 291: 2243-2252, 2004. 7. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the

Open access

Alin Albai, Mirela Frandeș, Ramona Luminița Sandu, Gabriel Spoială, Flavia Hristodorescu, Bogdan Timar and Romulus Timar

Abstract

Background and aims: Diabetes mellitus is the disease-challenge of our century, characterized by an increase in serum glycemia, which may lead to the occurrence of micro- and macro-vascular complications with serious consequences on both patient and public health. The Framingham risk score was obtained from a complex study and it estimates the individual risk of each patient to develop a cardiovascular event over the next 10 years depending on certain parameters (age, smoking, total cholesterol, HDL-cholesterol, systolic blood pressure). Our study main aim was to evaluate the cross-associations between the components of the metabolic syndrome, cardiovascular risk, diabetes-related biological parameters and chronic kidney disease in patients hospitalized due to poor metabolic control.

Material and methods: In this cross-sectional study, we enrolled 218 patients with type 2 diabetes, admitted in the Diabetes Clinic of the “Pius Brinzeu” Emergency Hospital Timisoara according to a consecutive-case population-based principle.

Results: We observed that the quality of the glycemic control is impaired in patients with higher age; the body mass index was positively correlated with HbA1c and hypertension accompanies diabetes in more than half of the cases. Moreover, we observed that high levels of LDL cholesterol are significantly correlated with high levels of HbA1c.

Conclusions: There was poor metabolic control in patients with associated complications such as hyperlipidemia, cardiovascular disease or chronic kidney diseases. Also, in most of the cases hypertension was associated with type 2 diabetes mellitus.

Open access

Maureen Jepkorir Cheserek, Gui-Rong Wu, Arsene Ntazinda, Yong-Hui Shi, Li-Ye Shen and Guo-Wei Le

: 458-66. 35. Yang RL, Shi YH, Hao G, Gang Hao, Wu Li, Guo-Wei Le. Increasing oxidative stress with progressive hyperlipidemia in human: Relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr 2008; 43(3): 154-8. 36. Tapia G, Cornejo P, Fernández V, Videla LA. Protein oxidation in thyroid hormone-induced liver oxidative stress: relation to lipid oxidation. Toxicol Lett 1999; 106: 209-14.